Ind-Swift Laboratories Ltd. (NSE: INDSWFTLAB, BSE: 532305) is a Manimajra, Chandigarh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,848 Cr, it ranks #1,037 by market cap among the 6,189 Indian listed companies on FinBizNet, and #34 of 86 in Medicinal Chemicals and Botanical Products. At ₹327.45 (as of 26 Oct 2026), the share price is 22.9% below its 52-week high of ₹424.75 and 271.5% above its 52-week low of ₹88.15. The share price is up 214.5% over one year and up 43.9% over three months.
| Current Price | ₹327.45 |
|---|---|
| Market Cap | ₹2,848 Cr |
| NSE Symbol | INDSWFTLAB |
| BSE Code | 532305 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 65.1 |
| Return on Equity | 3.24% |
| Return on Assets | 0.66% |
| 52-Week Range | ₹88.15 – ₹424.75 |
| 1-Year Price Change | +214.5% |
| 3-Month Price Change | +43.9% |
| Beta (1Y) | 0.77 |
| Dividend Yield | 0.00% |
| Headquarters | Manimajra, Chandigarh |
| Website | www.indswiftlabs.com |
| Revenue | ₹191 Cr |
|---|---|
| Net Profit | ₹25 Cr |
| Net Margin | 12.8% |
| EPS (Basic) | ₹2.84 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride,
1. Pharmaceutical Business-This segment develops, manufactures, and sells active pharmaceutical ingredients.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Ind-Swift Laboratories Ltd. | ₹2,848 Cr | 65.1 | 3.24% | ₹191 Cr | +214.5% |
Listed by market capitalisation. Ratios are shown for context only.
Ind-Swift Laboratories Ltd. is trading at ₹327.45, with a market capitalisation of ₹2,848 Cr.
Ind-Swift Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ind-Swift Laboratories Ltd. has a P/E of 65.1 and a return on equity of 3.24%.
Ind-Swift Laboratories Ltd. is listed on the NSE under the symbol INDSWFTLAB and on the BSE under the scrip code 532305.
Ind-Swift Laboratories Ltd.'s share price is up 214.5% over one year and up 43.9% over three months. Its 52-week range is ₹88.15 to ₹424.75.
In Q1 FY27, Ind-Swift Laboratories Ltd. reported revenue of ₹191 Cr and net profit of ₹25 Cr, with basic EPS of ₹2.84 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.